We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The product information for all Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists has been further updated to highlight the potential risk of severe acute pancreatitis with these products, including rare reports of necrotising and...
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
This study analyses the impact of these deletions on virus zoonotic infection characteristics and fitness
Get help to classify pharmaceutical products used to treat or prevent diseases or ailments (in humans or animals), including comparators used in clinical trials and placebos.
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
How to develop monitoring strategies for assessing levels of pollutants in the ambient atmosphere.
How to select compliance points for the assessment of risks to groundwater from land contamination.
When you need to do an environmental risk assessment, when the Environment Agency will do it for you, and how to do a risk assessment.
A summary of the main methods you should use to monitor for particulate matter in ambient air.
This report provides an updated harms assessment to the ACMD's previous reports on synthetic cannabinoid receptor agonists.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).